This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, X. Articles by Howell, S. B. Search for Related Content PubMed PubMed Citation Articles by Lin, X. Articles by Howell, S. B.

DNA Polymerase Accounts for the Reduced Cytotoxicity and Enhanced Mutagenicity of Cisplatin in Human Colon Carcinoma Cells That Have Lost DNA Mismatch Repair

Authors' Affiliation: Department of Medicine and the Cancer Center, University of California, San Diego, La Jolla, California

Requests for reprints: Stephen B. Howell, Department of Medicine 0058, University of California, San Diego, La Jolla, CA 92093. Phone: 858-822-1110; Fax: 858-822-1111; E-mail: showell{at}ucsd.edu.

The mutagenicity of cis-diamminedichloroplatinum(II) (DDP; cisplatin) and the rate at which resistance develops with repeated exposure to DDP are dependent on mutagenic translesional replication across DDP DNA adducts, mediated in part by DNA polymerase , and on the integrity of the DNA mismatch repair (MMR) system. The aim of this study was to determine whether disabling Pol by suppressing expression of its hREV3 subunit in human cancer cells can reduce the mutagenicity of DDP and whether loss of MMR facilitates mutagenic Pol -dependent translesional bypass. The HCT116+ch3 (MMR⁺/REV3⁺) and HCT116 (MMR^–/REV3⁺) human colon carcinoma cell lines were engineered to suppress hREV3 mRNA by stable expression of a short hairpin interfering RNA targeted to hREV3. The effect of knocking down REV3 expression was to completely offset the DDP resistance mediated by loss of MMR. Knockdown of REV3 also reduced the mutagenicity of DDP and eliminated the enhanced mutagenicity of DDP observed in the MMR^–/REV3⁺ cells. Similar results were obtained when the ability of the cells to express luciferase from a platinated plasmid was measured. We conclude that Pol plays a central role in the mutagenic bypass of DDP adducts and that the DDP resistance, enhanced mutagenicity, and the increased capacity of MMR^–/REV3⁺ cells to express a gene burdened by DDP adducts are all dependent on the Pol pathway.

This article has been cited by other articles:

				J. A. Brown, S. A. Newmister, K. A. Fiala, and Z. Suo Mechanism of double-base lesion bypass catalyzed by a Y-family DNA polymerase Nucleic Acids Res., July 1, 2008; 36(12): 3867 - 3878. [Abstract] [Full Text] [PDF]

				A. J. Krieg, E. M. Hammond, and A. J. Giaccia Functional Analysis of p53 Binding under Differential Stresses. Mol. Cell. Biol., October 1, 2006; 26(19): 7030 - 7045. [Abstract] [Full Text] [PDF]

				X. Lin and S. B. Howell DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance Mol. Cancer Ther., May 1, 2006; 5(5): 1239 - 1247. [Abstract] [Full Text] [PDF]